TUDCA Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about TUDCA dosing — protocols, safety, and where to buy.
Dosage Calculator
Calculate exact dosing for TUDCA.
Dosing Protocols
Beginner protocol (first-time user, general liver support, mild cholestatic issues).
- Dose: 250 mg, 1-2 times daily (total 250-500 mg/day)
- Timing: with meals (breakfast and/or dinner)
- Duration: initial 8-12 week trial
- Formulation: capsules or tablets from a reputable supplement manufacturer
- Monitoring: baseline liver function tests (ALT, AST, GGT, alkaline phosphatase, total bilirubin); recheck at 8-12 weeks
- Expected effects: subtle at this dose — slight improvement in liver enzymes if abnormal at baseline; subjective improvement in "liver-feeling" for some users; no dramatic subjective changes expected
- Adjustment: if well-tolerated with no adverse effects, may continue indefinitely or escalate to intermediate protocol
Beginner dosing is conservative and well-suited for general supplementation, mild cholestatic symptoms, or as an addition to an established longevity/liver-support protocol. It is also the dose range most compatible with intermittent use.
Intermediate protocol (established user, specific indication, higher-intensity support).
Dosing by indication:
- Supplement-channel liver support during oral anabolic steroid cycles: 500-1,000 mg/day divided with meals. Start 1 week before cycle; continue through cycle and 2-4 weeks post-cycle. Pair with baseline and end-of-cycle liver function testing.
- Primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC): 750 mg/day divided with meals, under hepatology supervision; TUDCA may be adjunctive or alternative to UDCA depending on response and availability.
- Intrahepatic cholestasis of pregnancy (ICP): 500-750 mg/day divided, under obstetrics/hepatology supervision.
- Metabolic syndrome / NAFLD: 500-1,000 mg/day, often combined with lifestyle interventions and metformin or berberine.
- General longevity/healthspan protocol: 250-500 mg/day as part of comprehensive longevity supplementation.
- Bodybuilding post-cycle therapy (PCT) liver recovery: 1,000 mg/day for 4-6 weeks following oral steroid cycle.
Intermediate protocol principles:
- Take with meals for optimal bioavailability
- Divide doses to maintain steady bile acid replacement effect
- Maintain consistent daily timing
- Combine with lifestyle factors (alcohol moderation, healthy weight, adequate sleep) for amplified effect
- Monitor liver function every 3-6 months during chronic use
- Watch for drug interactions with cholestyramine, colestipol, aluminum-containing antacids (separate by 4+ hours)
Follow-up labs:
- Liver function tests (ALT, AST, GGT, alkaline phosphatase, total bilirubin, direct bilirubin) at baseline, 8-12 weeks, then every 3-6 months
- If GGT or alkaline phosphatase were elevated at baseline, track these specifically for response
- If using for cholestatic disease, track additional markers per hepatology protocol
Duration considerations:
- For steroid cycle support: duration matches cycle plus recovery period
- For PBC/PSC: chronic ongoing use
- For metabolic syndrome: ongoing with lifestyle interventions
- For general longevity: ongoing based on comprehensive protocol
- No specific cycling-off requirements established for long-term supplement-dose use
Advanced protocol (clinical research doses, specific disease contexts, high-dose use).
Dosing by context:
- ALS (CENTAUR/AMX0035 protocol): TUDCA 1,000 mg twice daily (2,000 mg/day total) combined with sodium phenylbutyrate 3,000 mg twice daily (6,000 mg/day total). Administered continuously. Under neurology supervision. Note: Relyvrio has been withdrawn from the US market, but the dosing protocol remains the reference for researchers and patients electing to use the combination based on CENTAUR data.
- Advanced metabolic research doses: 1,750 mg/day as used in Kars et al. 2010demonstrating improved insulin sensitivity. Longer trials at higher doses have been conducted.
- Severe cholestatic disease refractory to UDCA: 1,500-2,000 mg/day under hepatology supervision, often in combination with UDCA or as a trial after UDCA non-response.
- Parkinson's disease research (UP-Parkinson's protocol): 1,000 mg BID with sodium phenylbutyrate; under clinical trial protocol or specialist supervision.
- Retinal degenerative disease (ophthalmology-guided): typically 500-1,000 mg/day under ophthalmology specialist supervision for retinitis pigmentosa or other retinal conditions.
Monitoring at advanced doses:
- Liver function tests (ALT, AST, GGT, alkaline phosphatase, total bilirubin, direct bilirubin) monthly × 3, then every 3 months
- Complete metabolic panel including renal function quarterly
- If using AMX0035 combination: serum ammonia and electrolytes (sodium phenylbutyrate component requires this monitoring)
- Clinical assessment for disease-specific endpoints (ALSFRS-R for ALS, UPDRS for Parkinson's, etc.)
- Side effect tracking including GI symptoms (diarrhea, bloating)
Stacking considerations at advanced doses:
- For ALS: typically combined with riluzole and/or edaravone (standard-of-care ALS medications); TUDCA is additive rather than alternative
- For neurodegenerative disease: often combined with CoQ10, creatine, Lion's Mane, and other neurosupportive compounds
- Cost considerations: advanced-dose TUDCA ($150-300/month supplement-channel; substantially more for pharmaceutical-grade) is meaningful; prioritize quality source over lowest cost
- Insurance typically does not cover off-label TUDCA use; most patients pay out-of-pocket
Contraindications at advanced doses:
- Severe pancreatic duct obstruction
- Severe extrahepatic cholestasis (mechanical obstruction)
- Severe decompensated liver disease (Child-Pugh C) without hepatology guidance
- Known hypersensitivity
- Pregnancy (unless specifically indicated for ICP under obstetrics guidance)
- Bile acid sequestrant use (separate dosing required)
Duration at advanced doses:
- For ALS: continuous ongoing use indefinitely
- For Parkinson's: continuous if positive response; reassess based on research/clinical guidance
- For research protocols: per study design
- For severe cholestatic disease: continuous long-term with hepatology supervision
Honest framing for advanced users: At ALS doses (2,000+ mg/day), TUDCA is pharmaceutical-dose territory. The CENTAUR positive-then-PHOENIX negative trajectory for AMX0035 creates legitimate uncertainty about magnitude of ALS benefit. Advanced-dose use should be pursued only under appropriate clinical guidance with clear expectations about likely benefit magnitude, documented monitoring, and willingness to discontinue if no objective or subjective response after reasonable trial period.
Commonly Stacked With
TUDCA stacks coherently with other hepatoprotective, antioxidant, and neuroprotective interventions. The specific combinations reflect the mechanism overlap — many hepatoprotective compounds address overlapping cellular injury pathways.
Well-motivated hepatoprotective combinations:
- NAC: complementary mechanisms — NAC provides glutathione precursor support for hepatic Phase II detoxification, while TUDCA provides bile-acid-based cytoprotection and ER stress reduction. The combination is broad-spectrum hepatoprotection and is commonly used during hepatotoxic drug courses, oral steroid cycles, heavy alcohol use, or as general liver support.
- Glutathione: similar rationale to NAC — direct GSH provision complements TUDCA's bile-acid effects. Often used in IV form for acute hepatoprotection protocols or oral/liposomal for chronic support.
- Milk Thistle (Silymarin): classical hepatoprotective herb with antioxidant and membrane-stabilizing effects. Stacks reasonably with TUDCA; mechanism overlap is modest so additive benefits are plausible. Typical dose 420 mg silymarin/day.
- Vitamin E (as mixed tocopherols, 400 IU/day): antioxidant support complementing bile-acid protection. Particularly relevant in cholestatic liver disease where vitamin E absorption may be impaired.
- Selenium (200 mcg/day): cofactor for glutathione peroxidase; supports the overall antioxidant infrastructure that TUDCA operates within.
- Omega-3 fatty acids (2-4 g EPA+DHA/day): anti-inflammatory and hepatic triglyceride-reducing effects; reasonable adjunct for NAFLD contexts.
- CoQ10: mitochondrial support complementing TUDCA's mitochondrial effects. Particularly relevant for aging, statin-associated myopathy, and cardiovascular conditions.
- Berberine: for NAFLD and metabolic syndrome contexts, berberine adds insulin sensitization and AMPK activation to TUDCA's ER stress and bile acid effects.
Neuroprotective combinations:
- Sodium Phenylbutyrate (PB): complementary chemical chaperone and HDAC inhibitor; this is the specific combination (AMX0035) studied in the CENTAUR ALS trial. The mechanistic rationale is sound — PB adds HDAC inhibition and ammonia scavenging to TUDCA's bile-acid effects. For ALS or other neurodegenerative applications, the combination has rationale even absent the specific Relyvrio formulation.
- Lion's Mane: NGF-promoting effects complement TUDCA's neuroprotection mechanism.
- Semax or Cerebrolysin: combination neurotrophic support for cognitive or neurodegenerative contexts.
- Vitamin D: general neuroprotection and immune modulation; adequate vitamin D status is prerequisite for most CNS-directed protocols.
- Creatine (5 g/day): mitochondrial support with some neuroprotective evidence; cheap and well-tolerated adjunct.
Metabolic syndrome combinations:
- Metformin: combination for NAFLD, prediabetes, or metabolic syndrome where both drugs have evidence-informed rationale.
- Berberine: additive for insulin sensitization and lipid improvement.
- Omega-3 fatty acids: for NAFLD triglyceride reduction.
Bodybuilding and oral steroid context:
- TUDCA + NAC: common bodybuilding stack for liver support during oral anabolic steroid cycles. Typical doses: TUDCA 500-1,000 mg/day, NAC 600-1,200 mg/day.
- TUDCA + Milk Thistle + NAC: classical "liver stack" for steroid cycles.
- Cycling: typically TUDCA is started a week before oral steroid use and continued through the cycle and for 2-4 weeks post-cycle to support liver recovery.
Potentially redundant or complex combinations:
- TUDCA + UDCA: these are the same base pharmacology; combining both is rarely additive and adds cost without clear benefit.
- TUDCA + high-dose vitamin E at 1000+ IU: high-dose vitamin E has shown mixed effects in some trials; the modest doses (400 IU) stack well but very high doses should be used with caution.
- TUDCA + bile acid sequestrants: absolutely avoid simultaneously — sequestrants will bind TUDCA and prevent absorption; separate by 4+ hours.
Lifestyle factors that amplify TUDCA effects:
- Adequate protein intake (supports hepatic protein synthesis and repair)
- Avoidance of chronic heavy alcohol use (alcohol is a major liver stressor)
- Maintenance of healthy body weight (obesity-driven NAFLD is a common liver stressor)
- Regular exercise (improves hepatic insulin sensitivity and reduces hepatic lipid content)
- Adequate sleep (supports all tissue repair and autophagy processes)
- Caution with additional hepatotoxic medications and supplements (ensures TUDCA has less competing insult to address)
Cycling considerations:
- For general health support: continuous daily dosing is typical
- For steroid cycle support: timed with the oral steroid cycle
- For ALS or neurodegenerative disease: continuous dosing typically
- No specific cycling-off requirements have been established for long-term TUDCA use at supplement doses
Timing with meals:
- TUDCA is typically taken with meals to optimize bile-acid-flow-based absorption
- Dividing daily dose into 2-3 portions through the day (with meals) is standard
- Taking on empty stomach is tolerated but may produce more GI side effects in sensitive individuals
Side Effects & Safety
Contraindications
**Absolute contraindications:** - **Known hypersensitivity to TUDCA, UDCA, or other bile acid components** — avoid further use - **Severe extrahepatic cholestasis due to mechanical bile duct obstruction** — requires mechanical intervention, not bile acid therapy - **Severe active cholecystitis or biliary pancreatitis** — defer bile acid therapy until acute condition resolved - **Completely obstructed gallbladder or bile duct** — bile acid therapy may be inappropriate; address obstruction first **Relative contraindications and use with caution:** - **Severe decompensated liver disease (Child-Pugh C)** — use only under hepatology supervision - **Known or suspected severe pancreatic duct obstruction** — discuss with specialist - **Pregnancy** — use only when specifically indicated (intrahepatic cholestasis of pregnancy, ICP) under obstetrics guidance; not recommended for general supplementation during pregnancy - **Breastfeeding** — limited data; discuss with obstetrics if use is needed - **Severe renal failure on bile acid sequestrants** — timing of administration is critical; separate TUDCA from sequestrants by 4+ hours - **Concurrent cholestyramine, colestipol, or colesevelam** — separate TUDCA dose by 4+ hours - **Concurrent aluminum-containing antacids** — separate TUDCA dose by 2+ hours - **Active severe diarrhea** — may be worsened by TUDCA; address diarrhea before beginning TUDCA - **Active inflammatory bowel disease flare** — may worsen diarrhea; discuss with gastroenterology - **Known gallstones with recent symptoms** — bile acid therapy may affect gallstone behavior; discuss with gastroenterology - **Severe hepatic cirrhosis with encephalopathy** — use under hepatology guidance only **Special considerations:** - **Source quality**: supplement-channel TUDCA quality varies; prefer reputable manufacturers with third-party testing - **Confusion with UDCA**: some products labeled TUDCA are actually UDCA; verify product identity - **Dosing precision**: bulk powder dosing should be done by weight, not volume estimation - **Storage**: keep dry, cool, and out of children's reach **Drug interactions requiring specific attention:** - **Bile acid sequestrants** (cholestyramine, colestipol, colesevelam): reduce TUDCA absorption; separate by 4+ hours. This is the most clinically significant TUDCA drug interaction. - **Aluminum-containing antacids**: may reduce TUDCA absorption; separate by 2+ hours. - **Estrogen-containing oral contraceptives**: theoretical increase in gallstone risk; usually manageable; discuss with prescribing physician if new TUDCA use on oral contraceptives. - **Fluoroquinolones**: minimal interaction but separation of timing is prudent. - **Warfarin**: TUDCA may theoretically affect warfarin absorption; monitor INR closely if initiating TUDCA on stable warfarin. - **Other medications**: TUDCA has minimal CYP450 interactions; most medications can be safely continued alongside TUDCA. **Laboratory interference:** - Does not interfere with standard lipid, glucose, liver function assays - Does not interfere with bile acid assays significantly except to elevate those specifically measuring TUDCA/UDCA - No interference with standard drug screens **When to seek medical attention:** - **Persistent worsening diarrhea**: evaluate for other causes; temporarily stop TUDCA and discuss with clinician - **New abdominal pain, particularly right upper quadrant**: evaluate for gallbladder or pancreatic pathology - **Jaundice (yellowing of skin or eyes)**: may indicate worsening of underlying liver disease; immediate evaluation - **Severe allergic reaction**: facial swelling, rash, difficulty breathing — emergency evaluation - **Signs of severe liver dysfunction**: severe fatigue, right upper quadrant pain, dark urine, jaundice **When to discontinue:** - Allergic or hypersensitivity reaction - Persistent intolerable GI side effects despite dose reduction - Worsening of underlying liver disease - Before planned surgery or major procedures (discuss with surgical team) - Pregnancy (unless specifically indicated for cholestasis of pregnancy under obstetrics guidance) - No objective benefit after 6-month adequate trial for a specific indication **Post-discontinuation:** - TUDCA's bile acid effects are relatively rapid; washout is typically 1-2 weeks - Liver function tests typically return to baseline or pre-TUDCA trajectory within 4 weeks - No withdrawal effects - Can be restarted after discontinuation if contraindication resolves **Honest framing:** TUDCA at supplement doses has exceptionally few absolute contraindications and a clean interaction profile. The main safety considerations are ensuring source quality, separating from bile acid sequestrants, and monitoring for rare side effects. For specific clinical indications (PBC, ALS, metabolic disease), appropriate specialist supervision guides contraindication assessment.
Additional Notes
Dosing ranges by context:
- Beginner / general liver support: 250-500 mg/day
- Standard supplement dose: 500 mg/day
- Cycle support (oral steroids): 500-1,000 mg/day during cycle, up to 1,000 mg/day post-cycle
- Cholestatic liver disease (PBC/PSC): 750 mg/day (clinical pharmacy doses)
- Metabolic research / advanced metabolic protocol: 1,500-2,000 mg/day
- ALS (AMX0035/CENTAUR regimen): 2,000 mg/day (divided BID) with sodium phenylbutyrate 6,000 mg/day
- Pediatric cholestasis: weight-based, typically 10-15 mg/kg/day under pediatric hepatology guidance
Formulations:
- Capsules and tablets (250-500 mg): most common form for supplement use; convenient, stable, measured dosing. High-quality brands include pharmacist-grade supplement manufacturers.
- Bulk powder: available from peptide/supplement suppliers; cost-effective for high-dose protocols but requires accurate measurement
- Liquid / solution: not commonly available; occasional compounded pharmacy option
- AMX0035 / Relyvrio (fixed-dose combination with sodium phenylbutyrate): pharmaceutical formulation; withdrawn from US market as of April 2024
Timing:
- With meals for optimal absorption (bile flow coincides with meals)
- Divided into 2-3 daily doses for steady-state exposure
- Morning and evening primary doses are most common
- Before bed dosing occasionally used but not standard
Storage:
- Room temperature in original container
- Dry, protected from light
- Capsules stable for 2+ years under proper storage
- Bulk powder stable when dry and properly stored
Bioavailability optimization:
- Take with meals containing some fat (aids bile acid absorption)
- Avoid simultaneous bile acid sequestrants (cholestyramine, colestipol, colesevelam) — separate by 4+ hours
- Avoid simultaneous aluminum antacids — separate by 2+ hours
- No specific food restrictions required
Cost considerations:
- Supplement-channel TUDCA 500 mg capsules: typically $30-60 for 60-count bottle (2-4 weeks at standard dose)
- Bulk TUDCA powder: more economical for high-dose protocols
- AMX0035 (while available): pharmaceutical-priced ($158,000/year list price before withdrawal)
- Quality TUDCA ranges $30-60/month for supplement-dose use; substantially more for high-dose protocols
Quality indicators:
- Third-party testing (Consumer Lab, NSF, USP-verified)
- GMP-compliant manufacturing
- Clear labeling of TUDCA content (not UDCA substitution)
- Reasonable price point (far below market typical suggests adulteration)
- Established brand reputation
Pharmaceutical-grade vs supplement-grade:
- Pharmaceutical-grade TUDCA is available in some European markets (e.g., Italian pharmaceutical registration)
- Supplement-grade TUDCA is the standard in US market
- For serious clinical indications (PBC, ALS), pharmaceutical-grade when available or high-quality supplement from reputable manufacturer
Bioavailability-enhanced formulations:
- No clearly superior bioavailability-enhanced TUDCA formulation has been validated
- Liposomal TUDCA products claim improved bioavailability but supporting evidence is limited
- Standard oral TUDCA at correct dose is generally adequate for all indications
Duration and cycling:
- For chronic use (PBC, ALS, ongoing support): continuous ongoing dosing without specific cycling
- For cycle support (oral steroids): duration matches cycle
- No accumulation or dose-escalation-to-tolerance issues reported with long-term use
- Dose reduction can be attempted after established response, but relapse of benefit may occur
Frequently Asked Questions
What is the recommended TUDCA dosage?
Dosage for TUDCA varies by protocol. Consult a qualified healthcare provider.
How often should I take TUDCA?
Administration frequency depends on the specific protocol. Consult current research literature.
Does TUDCA need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are TUDCA side effects?
TUDCA has an exceptionally favorable safety profile with decades of clinical use at the traditional cholestasis doses and accumulating safety data at the higher doses used in ALS trials. **Common side effects (5-15% at typical doses 250-1,000 mg/day):** - Mild diarrhea or loose stools (most common; usually resolves with continued use or dose reduction) - Mild nausea (uncommon; typically resolves) - Mild gastrointestinal discomfort (bloating, altered bowel habits) - Rare mild headache **Less common side effects (1-5%):** - Skin rash (rare) - Temporary pruritus - Changes in stool appearance - Mild liver enzyme fluctuations (paradoxically — TUDCA is generally hepatoprotective but in rare cases liver enzymes transiently rise) **High-dose side effects (ALS trial and research doses >1,500 mg/day):** - More prominent GI side effects (20-30% at >2 g/day doses) - Sporadic reports of dizziness - Transient headache - Occasional feeling of "warmth" or facial flushing **Rare serious events:** - Severe allergic reactions — extremely rare but possible with any biologically-derived or related compound - Worsening of pre-existing severe cholestasis (rare paradoxical response) - Hyperbilirubinemia at very high doses (rare) **Drug-drug interactions (limited but clinically relevant):** - **Cholestyramine, colestipol, colesevelam** (bile acid sequestrants) — reduce TUDCA absorption through binding in the intestine. Separate doses by at least 4 hours. - **Aluminum-containing antacids** — may reduce TUDCA absorption. Separate doses. - **Estrogen-containing oral contraceptives** — theoretically increase gallstone risk when combined with bile acid therapy; clinical significance unclear. - **Anti-hyperlipidemic bile acid-binding resins** — same as cholestyramine; separate dosing. - **Ciprofloxacin and other fluoroquinolones** — minimal interaction but separate dosing is prudent. **No significant CYP450 interactions.** Unlike many drugs, TUDCA does not significantly affect cytochrome P450 enzyme systems, giving it a very clean profile for concurrent use with most prescription medications. **Safety in specific populations:** - **Pregnancy**: TUDCA has been used for intrahepatic cholestasis of pregnancy (ICP) with apparent safety. UDCA is FDA Pregnancy Category B; TUDCA has a similar profile. Discuss with obstetrics for any pregnancy-related use. - **Lactation**: limited data; small amounts may be excreted in breast milk; consult obstetrics for nursing mothers. - **Pediatric**: Used in pediatric cholestatic liver disease (including inherited disorders). Weight-based dosing under pediatric hepatology guidance. - **Elderly**: no specific dose adjustments typically required. - **Renal impairment**: TUDCA has minimal renal clearance; dose adjustment not typically needed. - **Hepatic impairment**: used for many hepatic conditions; dose adjustment may be needed in very severe decompensated liver disease; discuss with hepatology. **Long-term safety:** Decades of UDCA use for PBC, and accumulating TUDCA clinical experience, demonstrate acceptable long-term safety. Chronic use for years has not been associated with organ toxicity, neoplasia, or other concerning delayed effects in the populations studied (primarily older adults with liver disease). **Quality considerations for supplement-channel TUDCA:** - Supplement-channel TUDCA is produced synthetically (not from bear bile; conservation and ethical concerns about traditional sources do not apply to synthetic TUDCA) - Manufacturer reputation and third-party testing matter — choose USP-verified or GMP-compliant manufacturers - Pricing of quality TUDCA is typically $30-60/month for standard 500-1,000 mg/day supplement-dose; products priced substantially below market range may be adulterated or underdosed - Watch for confusion with UDCA — some products labeled TUDCA are actually UDCA; TUDCA is more expensive due to manufacturing complexity - Bulk powder sources have greater quality variability than encapsulated products from reputable manufacturers **Special considerations for bodybuilding-dose users:** - Users on multiple oral anabolic steroid cycles who use TUDCA concurrently should recognize that TUDCA does NOT prevent the underlying hepatotoxicity of 17α-alkylated steroids — it is a mitigation, not a solution - Liver function monitoring (AST, ALT, GGT, alkaline phosphatase, bilirubin) is essential during combined oral-steroid-plus-TUDCA use - Seek medical attention for symptoms suggestive of significant liver injury (jaundice, severe fatigue, right upper quadrant pain, dark urine) **Monitoring recommendations:** - Baseline: complete metabolic panel including liver function tests (AST, ALT, GGT, alkaline phosphatase, bilirubin) - Follow-up: every 3-6 months during chronic use; more frequently if using concurrently with hepatotoxic medications or supplements - No specific TUDCA blood level monitoring is clinically indicated at standard doses
Where can I buy TUDCA?
Visit our vendor directory to find trusted sources for TUDCA.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
